A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
An HIV antibody achieves potency and breadth by binding simultaneously to two conserved glycans on the viral envelope protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
EMAN2: An extensible image processing suite for electron microscopy
Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.05.009 · Cited by 2,994
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
EMAN: Semiautomated Software for High-Resolution Single-Particle Reconstructions
Ludtke, S. J., Baldwin, P. R., & Chiu, W. (1999) · Journal of Structural Biology · doi:10.1006/jsbi.1999.4174 · Cited by 2,391
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citation
Cited by
Items 601–700 of 709
Lété, C., Markine-Goriaynoff, N., Machiels, B., Pang, P., Xiao, X., Canis, K., Suzuki, M., Fukuda, M., Dell, A., Haslam, S. M., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01722-15 · Cited by 3
“424 Interestingly, while the dense shield of glycans that decorate different viruses were believed to be 425 refractory to antibody recognition, several recent reports showed that it can be recognized by rare 426 neutralizing antibodies (49-53).”
BackgroundMoseri, A., Sinha, E. S., Zommer, H., Arshava, B. M., Naider, F. R., & Anglister, J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.11.088 · Cited by 3
“(c) Antibodies recognizing glycan dependent epitopes like PGT 128 [31].”
BackgroundAhmed, S., Shrivastava, T., Kumar, R., Kumar, M., Banerjee, M., Kumar, N., Bansal, M., Das, S., & Samal, S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129733 · Cited by 4
Bruxelle, J.-F., Kirilenko, T., Trattnig, N., Yang, Y., Cattin, M., Kosma, P., & Pantophlet, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-84116-w · Cited by 3
The Core Fucose on an IgG Antibody is an Endogenous Ligand of Dectin‐1
Manabe, Y., Marchetti, R., Takakura, Y., Nagasaki, M., Nihei, W., Takebe, T., Tanaka, K., Kabayama, K., Chiodo, F., Hanashima, S., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201911875 · Cited by 3
Targeted Analysis of Permethylated N-Glycans Using MRM/PRM Approaches
Reyes, C. D. G., Sanni, A., Mogut, D., Adeniyi, M., Ahmadi, P., Atashi, M., Onigbinde, S. B., & Mechref, Y. S. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3666-4_15 · Cited by 3
Molecular mechanisms of DNA lesion and repair during antibody somatic hypermutation
Hao, Q., Li, J., & Yeap, L.-S. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2615-1 · Cited by 4
“…are essential for the neutralizing potency and breadth against diverse antigens (Corti et al., 2010; Mascola and Haynes, 2013; Mouquet and Nussenzweig, 2012; Mouquet et al., 2010; Scheid et al., 2011; Walker et al., 2009; Walker et al., 2011; Wu et al., 2010; Wu et al., 2011; Zhou et al., 2010).”
Autoantibodies Induced by Chimeric Cytokine-HIV Envelope Glycoprotein Immunogens
Isik, G., van Montfort, T., Chung, N. P. Y., Moore, J. P., & Sanders, R. W. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303401 · Cited by 3
Self-citationMalaspina, A., Collins, B. S., Dell, A., Alter, G., & Onami, T. M. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0102 · Cited by 3
“4,18,19 At the VRC, structure-based vaccine design approaches have largely focused on eliciting Abs against the conserved CD4 binding site (CD4bs) that is vulnerable to several known bNAbs.”
van den Kerkhof, T. L. G. M., van Gils, M. J., Boeser‐Nunnink, B., Burger, J. A., Schuitemaker, H., & Sanders, R. W. (2016) · AIDS · doi:10.1097/qad.0000000000001177 · Cited by 3
“However, the available crystal structures of gp120 or trimer with PGT121 and PGT128 do not show any contacts of the antibodies with residue 333 [22,25,31,32].”
BackgroundSelf-citationNatural infection as a blueprint for rational HIV vaccine design
van Haaren, M. M., van den Kerkhof, T. L. G. M., & van Gils, M. J. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1232785 · Cited by 4
“can shield that surrounds the conserved HIV Env protein domains.(45,46) Lastly, bNAbs are often auto- or polyreactive.”
BackgroundDoran, R. C., Yu, B., Wright, M., O’Rourke, S. M., Yin, L., Richardson, J. M., Byrne, G., Mesa, K. A., & Berman, P. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02313 · Cited by 3
Carbohydrate-Based Vaccines against HIV/AIDS
Wang, L. (2012) · ACS symposium series · doi:10.1021/bk-2012-1102.ch006 · Cited by 4
Bailey, J. K., Horiya, S., Neralkar, M., Horváth, V., Nakamoto, K., Temme, J. S., Turra, R. J., & Krauss, I. J. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00539 · Cited by 2
Atabey, T., Derking, R., Newby, M. L., Bouhuijs, J. H., Snitselaar, J. L., Vink, M. A., Aldon, Y., Allen, J. D., Crispin, M., & Sanders, R. W. (2026) · Journal of Virology · doi:10.1128/jvi.01481-25 · Cited by 2
“Here, we hypothesize that this resistance may result from underoccupancy at glycan sites that are part of the outer domain intrinsic mannose patch (48, 71, 72).”
Self-citationOmondi, F. H., Sang, Y., Dong, W. W. Y., Mwimanzi, F. M., Cheung, P. K., Barad, E., Derza, Z., Anderson, K., Shahid, A., Mysak, V., et al. (2026) · mBio · doi:10.1128/mbio.03909-25 · Cited by 2
Upadhyay, A., Seow, J., Alguel, Y., Newman, J., Thakur, N., Hay, A. L., Tam, J. C. H., Nans, A., Orton, R. J., Bailey, D., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003882 · Cited by 2
Self-citationStructural Insights from HIV-Antibody Coevolution and Related Immunization Studies
Zhou, J. O., Ton, T., Morriss, J. W., Nguyen, D. N., & Fera, D. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0097 · Cited by 3
“65 The G57R H mutation, which occurred early, allowed intermediate IA4 (or a precursor) to latch onto the V3-loop backbone near the GDIR motif in a different manner from other V3-glycan bnAbs 35,66,67 ; the later R98T H mutation in the DH270.”
Cattin, M., Bruxelle, J.-F., Ng, K., Blaukopf, M. K., Pantophlet, R. A., & Kosma, P. (2022) · ChemBioChem · doi:10.1002/cbic.202200061 · Cited by 2
Glycopeptide Mimetics Recapitulate High‐Mannose‐Type Oligosaccharide Binding and Function
Lusvarghi, S., Ghirlando, R., Wong, C., & Bewley, C. A. (2015) · Angewandte Chemie · doi:10.1002/ange.201500157 · Cited by 2
Self-citationReichart, T. M., Baksh, M. M., Rhee, J., Fiedler, J. D., Sligar, S. G., Finn, M. G., Zwick, M. B., & Dawson, P. E. (2016) · Angewandte Chemie · doi:10.1002/ange.201508421 · Cited by 2
Liang, J., Zhai, L., Liang, Z., Chen, X., Jiang, Y., Lin, Y., Feng, S., Liu, Y., Zhao, W., & Wang, F. (2023) · Vaccines · doi:10.3390/vaccines12010019 · Cited by 2
“A variety of broadly neutralizing antibodies (bnAbs) have been generated with broad neutralization spectra and excellent antiviral activities in recent years [8–10], but their abilities to treat HIV-1 patients may be limited by the breadth and potency of their viral neutralization [11,12].”
BackgroundSelf-citationSantambrogio, C., Toccafondi, M., Donnici, L., Pesce, E., Francesco, R. D., Grifantini, R., Ponzini, E., Milanesi, F., Fragai, M., Nativi, C., et al. (2025) · ChemBioChem · doi:10.1002/cbic.202500106 · Cited by 2
The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies
Haynes, B. F., Saunders, K. O., Kelsoe, G. H., Mascola, J. R., & Nabel, G. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397933-9.00024-2 · Cited by 2
HIV Glycomics and Glycoproteomics
Bonomelli, C., Crispin, M., Scanlan, C. N., & Doores, K. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_1 · Cited by 2
Self-citationWei, C., Ekiert, D. C., Nabel, G. J., & Wilson, I. A. (2013) · Wiley eBooks · doi:10.1002/9781118636817.ch21 · Cited by 2
Self-citationAnti-Carbohydrate HIV Vaccine Design
Wang, L., Costantino, P., Geng, Y., & Zhang, H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_6 · Cited by 3
Zhao, W., Qiu, C., Shen, Y., Liu, W., Zhou, J., Xu, Y., Zhou, Z. M., & Chen, S.-Q. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.04.046 · Cited by 2
Human Immunodeficiency Virus Vaccines
Girard, M. P., & Koff, W. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00029-8 · Cited by 4
Role of HIV Glycans in Transmission and Immune Escape
Moore, P. L., Murphy, M. K., & Derdeyn, C. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_4 · Cited by 1
Structural Characterization of Biotherapeutics and New Modalities
Lello, P. D., & Lupardus, P. J. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch7 · Cited by 1
Figueroa, D. M., Valencia, T. R., Li, H., & Chen, B. K. (2026) · Journal of Virology · doi:10.1128/jvi.01542-25 · Cited by 2
“Because glycans account for roughly half of Env’s mass and many bNAbs recognize glycan-dependent epitopes (18–22), changes in glycan processing can further modulate antibody recognition.”
Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection
Grunst, M. W., Li, W., & Mothes, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1733684 · Cited by 1
“Despite low Env density on virions, some anti-HIV-1 Env antibodies neutralize far more potently in their IgG form than in their Fab form, suggesting Env cross-linking can contribute to neutralization potency (212 – 214).”
Relaño-Rodríguez, I., & Escolano, A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001063 · Cited by 1
Meeting report: 1st Middle East Vaccine Congress, 17–19th November, 2011 at Abu Dhabi, UAE
Spier, R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.12.075 · Cited by 1
Potent and Broadly Neutralizing Antibodies Targeting HIV Envelope Protein gp120
Song, M. (2012) · Future Virology · doi:10.2217/fvl.12.6 · Cited by 1
Johnson, M. (2012) · Materials and Methods · doi:10.13070/mm.en.2.132 · Cited by 2
Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys
Bischof, G., Shin, Y. C., Fuchs, S. P., Martinez-Navío, J. M., Lauer, W. A., Rakasz, E. G., & Desrosiers, R. C. (2017) · Gene Therapy · doi:10.1038/gt.2017.49 · Cited by 1
Cheedarla, N., Sundaramurthi, J. C., Babu, H., Anangi, B., Nesakumar, M., Ashokkumar, M., Vijayan, K. K. V., Tripathy, S. P., Swaminathan, S., Vaniambadi, S. K., et al. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0224 · Cited by 1
“Three amino acids at 166, 168, and 169 of NAB069 corresponding to 165ILE, 167GLY, and 168LYS of HXB2 (Table 5), also known to be essential for interaction with N160-specific bNAbs, were found to be present in the NAB069 env.(24,25) In addition to these 12 amino acids, 53 more residues were consistently predicted as cr…”
BackgroundGlycan Microarrays with Semi-synthetic Neoglycoconjugate Probes in Understanding Glycobiology
Palma, A. S., & Chai, W. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016575-00421 · Cited by 1
Dual Role of HIV-1 Envelope Signal Peptide in Immune Evasion
Upadhyay, C., Rao, P. G., & Feyznezhad, R. (2022) · Viruses · doi:10.3390/v14040808 · Cited by 1
Glikozylacja białek w infekcjach bakteryjnych i wirusowych
Kot, K., & Pocheć, E. (2023) · Postępy Biochemii · doi:10.18388/pb.2021_488 · Cited by 1
“Co ciekawe, na eliminacje szczepu HIV-1 JR-CSF wpływają zmiany struktury oligosacharydów w obrębie bliskiej pozycji N295, natomiast HIV2 i małpi wirus niedoboru odporności wykazują całkowitą oporność na przeciwciała [39].”
Development of gold nanoparticle-based antigen delivery platform for vaccines against HIV-1
Lin, F. W. (2015) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-4094 · Cited by 2
Reiche, S., Dwai, Y., Bußmann, B. M., Horn, S., Sieg, M., & Jassoy, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135320 · Cited by 1
Tian, M., Cheng, H.-L., Davis, J., Thompson, L. M., Chapdelaine-Williams, A. M., Tuchel, M.-E., Yin, A., Hu, J., Lin, X., Ye, A. Y., et al. (2026) · eLife · doi:10.64898/2026.03.30.715354 · Cited by 1
Characterization of Envelope-Specific Antibody Response Elicited by HIV-1 Vaccines: A Dissertation
Chen, Y. (2015) · eScholarship@UMassChan · doi:10.13028/m2z88m
“Second, the epitope of PGT128 consists mainly of glycans harbored by N301 and N332 while our mutagenesis study suggested that R20 does not need glycan for binding (data not shown).”
BackgroundInfluentialArchary, D. (2011) · ResearchSpace (University of KwaZulu-Natal)
Synthesis of Functional and Variable HIV-1 Envelope Glycoproteins
Clapham, P. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7729-7_4
“loop, in combination with proximal amino acids [ 208 ], while PG9 and PG16 [ 209 ]”
BackgroundHIV-1 vaccine epitope delivery based on foamy viral hybrid proteins and vectors
Muhle, M. E. (2015) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.25646/5339
“Selected broadly neutralising antibodies and their epitopes within HIV-1 Env Antibody Env Subunit Target Glycan involved Reference 2G12 gp120 Glycans Yes (68) b12 gp120 CD4bs No (69) VRC01 gp120 CD4bs No (70) PG9/PG16 gp120 V2/V3 loop Yes (71) PGT121/128 gp120 V3 loop Yes (72) D5 gp41 NHR No (54) HK20 gp41 NHR No (55)…”
Molecular evaluation of IgE reactivity in Hymenoptera venom allergy
Bantleon, F. I. (2014)
Antibody Guided Exploration of V3 Exposure on Subtype C HIV
Manhas, S. (2012) · Summit (Simon Fraser University)
Software Programs in Biomedical Research
Johnson, M. (2013) · Materials and Methods · doi:10.13070/mm.en.3.202
Jacob, R. A. (2014) · Open University of Cape Town (University of Cape Town)
Synthesis of carbohydrate antigens of the human immunodeficiency virus-1
Ambre, S. G. (2012)
Costa, M. R. (2016) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2w307
“These studies have shown some success in directing antibody evolution to sequentially bind designed immunogens, ending up with neutralization aimed at the CD4bs and N332 supersite (44–47).”
BackgroundHIV vaccine design based on in vivo evolution of quasispecies envelope proteins
Pissani, F. (2015) · doi:10.6083/m4cv4frm · Cited by 1
B cell fate following immunization : from memory B cells to plasma cells
Murillo, P. M. (2017) · Figshare
Structural Characterization of Recombinant Proteins and Antibodies
Lello, P. D., & Lupardus, P. J. (2017) · Wiley eBooks · doi:10.1002/9781119384434.ch5
Purification de Protéine par chromatographie sur colonne
Ritchie, C. (2012) · Materials and Methods · doi:10.13070/mm.fr.2.134
Understanding the interplay between HIV-1 diversity, humoral immune responses and viral fitness
Bandawe, G. P. (2014) · Open University of Cape Town (University of Cape Town) · Cited by 1
Rousset, C. (2018) · theses.fr (ABES) · doi:10.70675/7fd8ca27zde3bz4843z9801z7c29a5e7ea04 · Cited by 1
Lumngwena, E. N. (2017) · Open University of Cape Town (University of Cape Town)
Abrahams, B. (2019) · Open University of Cape Town (University of Cape Town)
Promotion of membrane interactions as a pathway for HIV antibody optimization
Insausti, S. (2021) · Communities in ADDI (University of the Basque Country)
Harley, A. (2021) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-20210609-63
Antibodies Targeting the Envelope of HIV-1
Mayr, L. M., & Zolla‐Pazner, S. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch11
Bruxelle, J.-F., Kirilenko, T., Trattnig, N., Yang, Y., Cattin, M., Kosma, P., & Pantophlet, R. A. (2021) · Research Square · doi:10.21203/rs.3.rs-140631/v2
Ito, Y. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718032489.793482265
Self-citationCowen, L. E., & Veri, A. O. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734605464.793556591
Ritchie, C. (2012) · 实验材料和方法 · doi:10.13070/mm.cn.2.134
Rademeyer, C., Korber, B., Seaman, M. S., Giorgi, E. E., Thebus, R., Robles, A., Sheward, D. J., Wagh, K., Jetta, G., Carey, B. R., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006641
Johnson, M. (2012) · 实验材料和方法 · doi:10.13070/mm.cn.2.132
Bruxelle, J.-F., Kirilenko, T., Trattnig, N., Yang, Y., Cattin, M., Kosma, P., & Pantophlet, R. A. (2021) · Research Square · doi:10.21203/rs.3.rs-140631/v1
Kaku, Y., Matsumoto, K., Kuwata, T., Zahid, H. M., Biswas, S., Górny, M. K., & Matsushita, S. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.932187
“Amino acid (AA) sequence alignment of heavy chain variable regions of 1C10, germline (IGHV3-30), and a sibling antibody of 1C10 lineage (3-32).”
BackgroundFinkelstein, M. T., Miller, E. P., Erdman, M. C., & Fera, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962939
Exploiting Glycans in Vaccine Design
Middleton, D. R., & Avci, F. Y. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162572-00262
Carbohydrate‐Based Antiviral Vaccines
Plata, A., & Fernández‐Tejada, A. (2023) · Wiley eBooks · doi:10.1002/9783527831326.ch3
Glycoconjugate Vaccine: An Effective Way to Combat Infectious Diseases and Cancers
Akter, F., & Kumar, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110281
Yue, L., Xu, R., Mclnally, S., Qin, Q., Rhodes, J. W., Muok, E. M. O., Umviligihozo, G., Brooks, K., Zhang, J., Qin, Z. S., et al. (2024) · Viruses · doi:10.3390/v16111706
“with N332/N334, N295, or N301 playing important roles in antibody susceptibility 46–48].”
Structure-Guided Vaccine Design
Alam, N., & Higgins, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00157-5
Parallel evolution of the elite neutralizer phenotype in divergent HIV-1 clades
Mesa, K. A., Li, S. W., Hutchinson, J. M., O’Rourke, S. M., Alexander, D. L., Yu, B., Shen, X., Wrin, T., Petropoulos, C. J., Berman, P. W., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00433-25
“Whereas N332 is central to potent bNAbs and broad serum responses (2, 5, 14, 16, 23–27), the epitopes of other glycan-dependent Nabs with lesser breadth have been found to include potential N-glycosylation site (PNGS) contacts at 276, 295, 334, 339, and 392 (19, 28–33) that would also be subject to…”
Thomas, P. (2023) · UCL Discovery (University College London)
Mimetische Peptide als molekulare Werkzeuge zur Analyse des HIV-1 Eintrittsprozesses
Groß, A. (2013) · OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) · Cited by 1
Benjelloun, F. (2013) · theses.fr (ABES) · doi:10.70675/3bf8d428z94b9z4ddaza841zdfaab92f44a3
“Par microscopie électronique, il a été démontré que PGT127 et 128 sont capables de relier les spicules à la surface des particules virales, ce qui augmente leur affinité par l’avidité, mais pas sur la surface des cellules [224].”
BackgroundCaractérisation des activités antivirales des anticorps anti-VIH-1 et anti-SARS-CoV-2
Dufloo, J. (2021) · theses.fr (ABES) · doi:10.70675/215798eaz7f82z4e57za8eazf4453d37b8c8
Structure of the hiv-1 envelope glycoprotein in complex withnovel broadly neutralising antibodies
Pedenko, B. (2024) · theses.fr (ABES) · doi:10.70675/526016b0zc0e2z40e2za732z121b7254e0f9
Myers, A. W., Chandravanshi, M., Whitmore, L. S., Kohrn, B. F., Negash, A., Nguyen, D. N., Ralli-Jain, P., Cruickshank, K., Upadhyay, A. A., Charles, T., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014268
“On the other hand, mAb 4 likely neutralizes BG505 pseudovirus through a CD4-independent mechanism, such as slowing entry of adsorbed virions [27] or inter-trimer crosslinking on the virion [2,28], which have been attributed to V3-high mannose binding site bnAbs.”
Jiao, R., Liang, L., Tian, E., Yao, Y., & Liao, W. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110195
Metadata
- Authors
- Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C.-H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- University of Washington (US)
- University of Oxford (GB)
- Cornell University (US)
- Progenics Pharmaceuticals (United States) (US)
- National Institutes of Health (US)
- Imperial College London (GB)
- Japan Science and Technology Agency (JP)
- Corresponding author
- Pejchal, Robert
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Burton, Dennis R.
- Wilson, Ian A.
- ORCID
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Wang, Sheng-Kai
- Stanfield, Robyn L.
- Julien, Jean-Philippe
- Crispin, Max
- Depetris, Rafael
- Cupo, Albert
- Liu, Yan
- McBride, Ryan
- Ito, Yukishige
- Sanders, Rogier W.
- Paulson, James C.
- Feizi, Ten
- Wong, Chi-Huey
- Moore, John P.
- Olson, William C.
- Ward, Andrew B.
- Poignard, Pascal
- Schief, William R.
- Burton, Dennis R.
- Wilson, Ian A.
- Venue
- Science
- Published
- 2011-11-25
- Volume
- 334
- Issue
- 6059
- Pages
- 1097-1103
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3280215
- OpenAlex
- W2128579789
- Cited by
- 694
- References
- 75
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 18 · 2023: 19 · 2022: 25 · 2021: 35 · 2020: 34 · 2019: 37 · 2018: 54 · 2017: 54 · 2016: 62 · 2015: 70 · 2014: 69 · 2013: 105 · 2012: 72
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Canadian Institutes of Health Research (HFE-224662)
- Engineering and Physical Sciences Research Council (EP/G037604/1, GR/S79268/02)
- National Cancer Institute (Y1-CO-1020, U01CA128416)
- National Institute of General Medical Sciences (Y1-GM-1104)
- National Institute of Allergy and Infectious Diseases (AI-33292, F32AI074372, AI74372, R37AI033292, R56AI084817, P01AI082362, AI082362, R01AI033292, R01AI084817, AI84817)
- National Center for Research Resources (P41RR001209, RR017573, P41RR017573)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1, broadly neutralizing antibodies, gp120, glycan shield, V3 loop, antibody penetration
- MeSH terms
- Antibody Specificity, Epitopes, Binding Sites, Antibody, Carbohydrate Conformation, Cell Line, Disaccharides, Glycosylation, Humans, Hydrogen Bonding, Immunoglobulin Fab Fragments, Mannose, Mannosides, Models, Molecular, Mutation, Oligosaccharides, Polysaccharides, Protein Conformation, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, Protein Structure, Tertiary, Crystallography, X-Ray, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.